EU/3/18/1991

About

On 21 March 2018, orphan designation (EU/3/18/1991) was granted by the European Commission to TurnKey PharmaConsulting Ireland Limited, Ireland, for docosahexaenoic acid ethyl ester (also known as SC411) for the treatment of sickle cell disease.

Key facts

Active substance
Docosahexaenoic acid ethyl ester
Disease / condition
Treatment of sickle cell disease
Date of decision
21/03/2018
Outcome
Positive
Orphan decision number
EU/3/18/1991

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

TurnKey PharmaConsulting Ireland Limited
Ellerman House
Cratloe Wood
Cratloe
County Clare
Ireland
Tel. + 353 86 844 6816
E-mail: SC411@sancilio.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating